text:
Dang it, AF showed today. That really sucks. According to my temps and opk I should be 4 dpo. I don't know what the heck is going on.
Dang it, AF showed today. That really sucks. According to my temps and opk I should be 4 dpo. I don't know what the heck is going on.
Last edited by ktbug; 04-06-2011 at 08:52 PM.
Last edited by ktbug; 04-06-2011 at 08:52 PM.
Sorry guys, I didn't want to hurt anyone with a pic of my son in my siggy. Please let me know if it offends anyone.
Yes it has to be full blown AF. Lots of red blood and clotting. My OB said that I probably should not bother with opk's after about CD25. It makes sense. I think that this last really late O was a quality issue. I did have another baseline u/s today for the next round, but I thought I saw some pretty big follies or cysts. Not sure though. We'll see what my OB says after she's looked it over. If all is good, I am starting 100mg today. I am feeling so discouraged right now, I hope she has good news!
Kate, I bet you are getting all excited and obsessing!
ETA: Got a call back from my OB and there is 1 cyst over the ok size limit. She wants me to take birth control pills for a cycle to resolve it. I haven't taken birth control in 15 years! I guess I will do what she says. I trust her. Really bummed that I'm out for a cycle though. Good luck ladies.
Last edited by sunkiss; 07-01-2011 at 04:36 PM.
Anyone experience the inability to deal with emotions when they come on strong? Like, more so temper tantrums.
I feel like in the last 4 cycles since I started Clomid/Femara I am able to maintain my cool for a period of time and once I hit my limit, I blow. I can't control myself. I have blown up at my husband for the dumbest things because little things had already happened and one little thing tipped me over.
I've only used 50mg of Clomid starting in March-May cycles and this cycle 5mg of Femara.
I'm afraid injects are going to make me flip my lid even more. I avoid most family because I'm afraid to blow up in front of them and look like a jerk. I've never really been like this before. Emotional at times but never like this.
I too am trying to conceive. It has been 19 months for me and I am trying my best to trust in the Lord each and every day, knowing that He will provide when He sees fit. I am starting Clomid for the first time in less than a week. I am doing days 3-7 on 50mg. I have heard of taking Mucinex or Robitussin afterwards. Do you guys know which is better, how much you take, and for how long? I have been told that my progesterone does not show that I am ovulating, but I do not know my levels. I was tested recently for hypothyroidism, but do not have it. I have never had any problems or abnormal pains and have always had a fairly regular cycle. Its disheartening, but I know He is in control. I definitely need a support group though because all of my friends are getting pregnant and it is difficult for them to understand the pain and frustration that comes with trying to conceive. All of them conceived within 3 months of trying...
nice thanks for sharing
Hope everyone else is having a good clomid cycle and we all get BFP's this month!!! Well hopefully we get some BD in this month and get a BFP..DH is trying to convince me it's going to be ok and that we will be able to BD starting tomorrow. But we will see.. I kind of had a melt down last night. I'm also dealing with the fact that my DS is almost grown, So I've been having empty nest syndrome. My husband thinks I'm going through a mid life crisis, I told him I'm not that freakin old yet and that he needs to remember he is a year older then me and he will go through it before I.
Ladies, I know some of you by being in the IVF sisters. My sister has taken one round of Clomid and they tested her for ovulating and her progesterone only got to 4...well after 44 days she thought I am just going to take a pg test and it was positive. Her first lot of numbers were 94 but then 4 days later they were only at 104 and she had dark spotting. We all thought she was miscarrying. Then it went to 218. Still spotting dark red and brown, cramping a bit. She still thinks she is miscarrying.
I just can't let go yet (have not told her) her numbers are increasing 60% every 72 hours. Has anyone had a viable pregnancy after yucky BETA numbers like this???????
Hello ladies, sorry if I make mistakes in writing, I'm from Europe, from the country where English is not native language. I read this forum and I see that there are many women with a similar problem as mine. I hope that we will one day soon fulfill our greatest desire for babies.
I have a problem with my PCO-s, i started using clomid, 5 days, one pill 50 mg a day, but my ovaries did not react well. The follicles were small and there was no ovulation. The follicles were broke before their time, about 20 mm, which means that they failed to reach the desired size.
I sincerely ask the ladies who are experienced in this to tell me a little more about this problem, why it happened, if ones had a similar case and how to solve the problem, that I soon became pregnant?
Thank u very much.
Impatient girl they could try upping your Clomid. I didn't respond to 50 or 100 had to do 150 and 200 to Ovulate. Hoep your get your soon!
Things are a little crazy, but I'm loving every minute of it My Blog
Well I got a BFP about 2 weeks ago and the doc has put me on Crinone 8% progesterone gel. Has anyone used this and sucessfully carried a baby. At 4 weeks, my level was a 3. I am now at 6 weeks and feel good...
This month, I am just paranoid that I am going to miss something so I am going to test w/ FMU and at night.
Cable Sleeves
Hi everyone! I am new to this site and am very much in need of some support. My husband and I have ttc for 3 years now and we've experienced one miscarriage which was almost 2 years ago. No pregnancies since then The past 9 months have been filled wih testing and appt. after appt. Everything has come back normal though, which is definitley a good thing. Finally my doctor has decided to put me on Clomid! Today is Day 1 of starting this new cycle. I am so excited but don't want to get my hopes too high. It's very comforting to hear everyone's stories and what they experience on this medication. I am looking forward to reading more about the outcome of this for everyone.
Last edited by Songbird_kay; 02-10-2012 at 11:44 PM.
Me: Robin Follow As Natalie Blooms DH: Aaron
No advice to give just wanted to wish you luck!
I know I released eggs and I know my husbands spermies are in excellent shape.. so I figuring something most likely went wrong with implantation. Well, what ever it was I'm on another month of Clomid as well as a new plan. I'm on CD 6 and am taking Clomid CD's 5-9, day 10 I'll start Mucinex and day 12 I'll start OPK's.


text:
New York sports titles
A compilation of every player, manager and head coach to suit up for a major New York sports champion. Includes football, baseball, basketball, hockey and soccer titles.
Advanced search
These are the top aggregated results based on the search you performed.
Top playersView full list »
Top positions
- Forward (S) 46
- Defense (S) 40
- Midfield 33
- Goalie (S) 14
- Coach 4

subset: commoncrawl


text:
Washing is fun: with the right know how it becomes a pleasure – and gets your laundry cleaner.
Henkel sets standards with its brands: Persil – Germany's No. 1 detergent – offers premium quality and utmost care for your laundry. Weißer Riese (the White Giant) has been demonstrating for decades how tough he is on stains. And Spee (Fox): that's the clever way of washing.


text:
De Gaulle International Carry-On
best complemented withPrevious Page
Narita Slim Brief
Barajas Kit
Kingsford Backpack
Camden 4 Wheeled Expandable Long Trip
McCarren Zip Top Crossbody
Shoe Bags
Passport Case
Electric Adaptor with Ballistic Case
- Arrivé
- De Gaulle International Carry-On
- Style #: 25020
- Free Shipping! See Details
Arrivé is meticulously appointed with the finest aesthetic and engineering features imaginable. It combines contemporary understatement with the ultimate functionality of Tumi's advanced technology. Signature details include smooth calfskin trim, elegant and resilient HTLS Polyester® fabric, striking chrome accents, custom-made handles, intelligent interior organization and numerous patented components. This compact, expandable wheeled carry-on is sized to meet international carry-on guidelines. It features numerous accessory pockets and a removable suit sleeve. Note that hanger shown is not included with the case; it may be purchased separately (#0052).
- Monogramming Available: Yes
- External Dimensions (wheeled items include handles and wheels) H x W x D: 22" x 14.5" x 9"
- Expanded Depth: 10.5"
- Construction Material: Fabric
- External Features:
- Front zip pockets
- Telescoping handle with leather wrap
- Top, side and bottom carry handles
- Wheels with inset leather
- Protective bottom feet
- Add-a-Bag strap
- Removable lock
- Internal Features:
- Zip pockets
- Mesh pockets
- Tie-down straps
- Hanger bracket
- Removable suit sleeve
- Embossed lining
Everyday Free Returns
We want you to be fully satisfied with every product that you purchase from www.tumi.com. If you are not satisfied with a product that you have purchased, you may return the product within 30 days of delivery for a full refund of the purchase price, minus the shipping, handling, gift box, and other charges. Please note, however, that monogrammed and personalized items, including Accent Your Alpha, cannot be returned. Return shipping is free. You will be provided with a pre-paid UPS domestic label to return your purchase. If you cannot find the prepaid shipping label, please call our Customer Service Department at 1-800-299-TUMI (8864) or contact us by email.
We ask that the product be unused, in original boxes (whenever possible), and with all paperwork, parts and accessories in order to ensure credit. Sale merchandise will be issued a credit at the current selling price. Unused items purchased on www.tumi.com can also be returned to a US Tumi full price location. Please make sure to have all paperwork, parts and accessories to ensure credit. Store credit will be issued for items without documentation.
Welcome to the world of Tumi – the finest international brand of travel, business and lifestyle accessories. Since our founding in 1975, Tumi has been dedicated to providing our customers with an outstanding ownership experience.
Specifically, we make three commitments to our customers:
1. You will enjoy using our innovative products that are designed and manufactured to be the best;
2. You will experience world-class, after-sales customer service;
3. For a limited time after you purchase a Tumi product from an authorized Tumi store or dealer, you will be covered by our Limited Warranty.
Tumi's warranty extends to the original owner; it is straightforward and comprehensive, and just part of the total Tumi ownership experience.
Please click here to learn more about the Tumi Warranty.
The Tumi Difference
Add-a-bag system
Quickly and easily add another travel piece or business case using our patented Add-A-Bag hook with secure fastened tab closure that holds in excess of 200 pounds. Also, many Tumi business cases and totes feature a back sleeve that slips over extended luggage handles allowing you to stack and carry heavier bags on your wheeled luggage. Used together, these features allow travelers to effortlessly carry two or three items at the same time with one hand.
Easy Glide Wheels
Our state-of-the-art in-line wheels incorporate sealed steel ball bearings and are mounted on solid steel axles in custom-designed, shock-absorbing bushings. They roll smoothly and quietly for hundreds of miles.
Omega Closure System®
Tumi's patented closure system significantly reduces the risk of damage to the zipper. The Omega zipper puller is designed to break away from the bag if it becomes caught. The puller, rather than the entire zipper, is then quickly and easily replaced.
Tumi Tracer®
The Tumi Tracer® is an exclusive, complimentary program that helps reunite Tumi customers with their lost or stolen items. The core of the program is a unique 20-digit individual product number printed on a special metal plate that is permanently affixed to Tumi products. That number, along with the owners contact information, is entered into our Tracer database when a bag is registered with us, and used to help aid in the recovery of lost or stolen items that are reported to us.
Aircraft Grade Aluminum Extension Handle
The tubing of our telescoping handles is made from aircraft-grade aluminum, making them both lightweight and extremely sturdy.
HTLS® Fabric
Engineered for performance as a luggage fabric, HTLS® combines high-tenacity durability with low shrinkage properties that help maintain the shape of the fabric through a variety of temperature and weather conditions


text:
Presenting a cantata with your church choir is a wonderful way to prepare your congregation to celebrate the birth of… read moreSeptember 12th
The concert schedule for lots of schools is the same year in and year out. Consider shaking things up this year with… read more
Love Came Down at Christmas stantonssheetmusic.wordpress.com Presenting a cantata with your church choir is a wonderful… read moreSeptember 13th
PBJ & Jazz has their last event of the season today! Don't miss out! PBJ & Jazz | Jazz Arts Group of Columbus… read more
Stanton's has built a reputation as "The Sheet Music Specialists".
Can't attend one of our clinics? Visit Stanton's Virtual Workshop.
In just a few minutes you can have your favorite song printed and ready to play.
Online Service for Music Educators.
Title: Tahiti Trot
Voicing/Format: Concert Band
Publisher: Belwin Mills Publishing Corp
Composer: Shostakovich/Youmans
Arranger: Brubaker, Jerry
Catalog #: 30828
Grade: Gr-4
Series: Symphonic Band Price: $75.00


text:
You can follow the discussion on USMNT Daily Update: How Klinsmann has embraced the 'empty bucket' philosophy without actually playing it without having to leave a comment. Cool, huh? Just enter your email address in the form here below and you're all set.
Top Headlines
- SBI Weekend Rewind: Red Bulls top Sounders; Chandler earns first hometown start; and more
- Americans Abroad: Weekend Rewind
- European Weekend Rewind: Late Lampard goal earns Man City draw with Chelsea; Juve tops Milan; and more
- USL Pro Playoff Rewind: Sacramento pulls off dream comeback, Harrisburg continues Cinderella run
- Soccer Sunday: Your Running Commentary
- Saturday College Rewind: Saint Louis beats Creighton, Gonzaga upsets UNLV, and more
- Must-See Goal: Pablo Hernandez
- Gordon's winner caps Galaxy rally past FC Dallas
- Wright-Phillips hat trick leads Red Bulls over Sounders
- Gritty Crew win snaps Revolution winning streak
Key Soccer Sites
Top Soccer News Sites
SBI Soccer Blog Roll
MLS Team blogs


text:
Check this out... women have always said that men make a much bigger fuss over being sick than women do. Well- now scientists have found out that it's actually true! The more "manly" a guy is, the more susceptible they are to getting sick. Much lower immune system. It's NOT just "suck it up" as we women would always say. They actually are sicker than women! Ha!!
Maybe I should feel bad.... naaaaahhhhhh


text:
Logo USC Trojans Can KoozieItem Number: 17956646
Price: $4.99
Free Shipping Eligible on Qualifying Purchases Over $49! Up to $15 Shipping Credit. (See Promotion Details)
Product Information
Customer Reviews
Cheers to a winning season with the Logo® USC Trojans Can Koozie. This neoprene team-colored koozie features a screen-printed logo to represent the Trojans at the tailgate or on the couch. With a fold-flat feature for easy storage and travel, this koozie fits most cans and bottles. Represent USC every day with the Logo® Can Koozie.
- Team-colored, screen-printed team logo koozie
- Fits most cans and bottles
- Neoprene fabric for easy grip
- Folds flat for storage
- Officially licensed collegiate product
- Logo
Country of Origin: Imported


text:
With hundreds of headphones to choose from, finding the right pair can sometimes be difficult.
Learn from our other customers and browse our selection of best selling headphones.
Choosing the best headphones will take work and careful research. Each individual has slightly different tastes when it comes to choosing headphones that have the right mix of bass versus the other sounds. One easy place is to start by researching the best selling headphones. These headphones have been tested by other consumers and have risen to the top through the excellent value they offer. When you are looking for the perfect sound, you need to find the best headphones available.
The best over ear headphones will provide high quality sound. You can choose between wireless headphones that make it easy to do other things while you are listening to music and wired headphones. Wireless headphones prevent you from shorting out your headphones with a kink in the wire. Over ear headphones best offer a better sound experience, since they more effectively block out outside noise. The best headphones will be comfortable with a high sound quality.
If you are thinking about purchasing best selling headphones, you should carefully read the reviews to gauge which are the best over ear headphones for you. Over ear headphones best offer a comfortable fit and will stay securely in place. If you have smaller ears or if you struggle to find a comfortable in ear bud then the best over ear headphones are for you. The best headphones are the ones that offer both top quality sound and comfort so you can truly enjoy your music and concentrate on your work.
Headphones.com offers the best selling headphones, and the best over ear headphones on the market. We also offer reliable shipping and competitive prices on products for you. Over ear headphones best offer comfort and high sound quality, and Headphones.com can deliver them to your door. When it is time to choose a new set of headphones, it is important to choose both utility and comfort. Take the time to read the reviews and then purchase the ones that best match your needs, whether they are for your work as a music producer, film editor or just for your own personal enjoyment, you will benefit from using the best headphones possible.


text:
> Home > Brands & Solutions > Beauty Care > Hair > Retail > Care
Henkel Beauty Care offers many care products that are specifically formulated for your hair needs.
Here is a list of all hair care brands available in retail stores. Click on each logo to learn more about the brand, its history and products.


text:
By Ryan ErmanniFox 2 NewsWOODHAVEN, Mich. (WJBK) -- Army Specialist Matthew Smith, home from his second tour of duty in Afghanistan, made a visit to Erving Elementary in Woodhaven Tuesday to surprise his nephews that he hasn't seen in almost a year."It's just a great day seeing these little guys. I talk to them on Skype and on the phone, and just missing part of their lives, watching them grow and everything, it's hard, but coming home and seeing these guys for the first time, it's a great feeling," said Smith.But perhaps the happiest person at the school on Tuesday was Smith's mother, who set up the surprise visit for her grandsons at school."I'm very proud of my son and just thank God he [came] home safe and everyone in his unit," said Laurel Smith. "It was awesome to see that Saturday, the buses rolling in, and all of them are reunited with their families again."
WHBQ-TV | Fox 13 485 S. Highland St.Memphis, TN 38111Main Station: (901) 320-1313Newsroom: (901) 320-1340


text:
What an awful story. A father left his 22 month old son in an SUV all day, was charged with murder and cruelty to children in the first degree. He left the toddler unattended and strapped into a child car seat in a parked vehicle for 7 hours, after which the child was found deceased.
It's not like he forgot some groceries, this is a child we are talking about, unreal.


text:
Rated 4.4 out of 5Â by 12 reviewers.
Kids' adidas Soccer Shoes
Predator Absolion LZ TRX FG Cleats
Black/Running White (F32554)
Size Chart
+ Save To Wishlist
Rated 5 out of 5Â by Stopper9 Walkin on clouds I got these cleats to replace an extremely old pair that I'd had for forever, and the difference is amazing. The comfort level is stunning, I feel like it's unnatural for a pair of cleats to be this comfortable, and my touch is visibly better, just because of the zones. Also they just look freaking sick, I got the white with red zones and black stripes, and they definitely draw the eye. I feel like my game is much better now, and my endurance level has gone up because of the good support and comfort. I would give these cleats 6 stars if possible, I would recommend them for any soccer player who wants to up their game. September 2, 2013
Rated 5 out of 5Â by Manny06 Must buy shoes These cleats are amazing, they are definitely for you if you want some great shoes for a low price. I used them for a game the same day they were delivered and I really liked the fit they were true to size and more comfortable than mercurials. Honestly I did not feel a difference in weight. They also offer more protection when it comes to getting stepped on or kicked etc. I look forward to using them for the rest of soccer season. In conclusion I have happily switched to team adidas and will buy from here much more often. December 8, 2013
Rated 5 out of 5Â by CP17 great shoe! They're great cleats and they improved my curve, my pass and my shooting overall great boot. September 27, 2013
Rated 2 out of 5Â by Northside Spirit Very comfortable fit, clunky average performance They appeared to be of extremely high quality and fit my feet better than any other shoe for comfort and no blisters after playing! But on field, they felt heavy, stiff and I found it hard to get much power or loft into shots; they would roll along the ground very often compared with if I had other boots on. Also played with friends using the official Brazuca match ball which is a v speedy ball and it was impossible to have a light touch when receiving the ball, it would ping off my foot every time and get far away from me. I never had this experience with other boots. Also I noticed the studs are shorter than the top tier models, which makes it feel flat and hard to get on your toes for speed. No wow factor, very average performance. May 16, 2014
Rated 5 out of 5Â by Jahza14 Great shoe I have just had then for a week and I can already tell that they are awesome. The traction on them is insane!!! September 14, 2013
Rated 4 out of 5Â by gianmil my son love it, but litle hard to clean.. September 20, 2013
Rated 4 out of 5Â by On the up and up Decent pair The style is nice. The change in material density that makes the nice pattern also causes the shoe to bend a little unaturally. It took awhile to get use to. The tongue does rub against the shoe causing a squeaky noise when walking. They are comfortable enough and i will continue to use them. January 28, 2014
Rated 4 out of 5Â by Laura77 Predador Absolion Cleats My son play soccer and loves the addidas cleats, he prefer addidas because he says the addidas cleats are more confortable that other brads and the material are the high quality. Also the big stars of soccer using addidas cleats November 22, 2013
Rated 5 out of 5Â by sporty pink great boot i bought these for my husband and he loves them. they are super soft and comfortable. very much worth the price! December 27, 2013
Rated 5 out of 5Â by kaka-ali worth the price!! This are one of the best kits I have bought. Very comfortable and light. I love them!! December 11, 2013


text:
This design plays beautifully with opposites. The graceful curves of a center oval gem are echoed by back to back arcs on each side accented by eight brilliant gems. Bold but delicate too, you'll find it goes with everything you wear. See Details
Gemvara jewelry is truly personal: you design it, choosing gems and metals to celebrate your story, and we craft it just for you. We'd love to help you find your perfect piece! (more)What quality are your gemstones?
They are all-natural and hand selected fine quality. (more)


text:
Long Yoga Pant PLUS
Was: $49.00
Now: $19.99
Now: $19.99
closeThe style was added to your shopping bag
Check out now
Continue Shopping
Add to Wish ListCheck out now
Studio, gym or lounge: slip into comfort and fashion forward style with our all-new yoga pant. Maximize your look with our new V-Neck or Tank Top to ensure you're fabulous, no matter the activity! Be sexy in everyday essentials with star power from Frederick's of Hollywood.
- Curve-hugging bootcut silhouette
- Stretch, foldover waist
- Ruched detail at back
- 33" inseam
- Made in USA
Style 75004


text:
Tahiti free surf
Sunday arvo lay day in tahiti.....place is the best
Tahiti feast
Fresh Tuna every day along with endless fresh fruit and food is hard to take.
HUGE swell heads for Tahiti
With Rd 1 done, and event directors looking froward to the swell later next week, possibly around Thurs / Friday, with some calling Saturday as the biggest they have ever seen on a forecast for Teahupoo..?????? WOWSERS!!
Fish Tales @ US Open
Check out Paul Fishers take on the US Open....
Kerr @ Teahupoo
Josh Kerr surfed an amazing heat today, but narrowly got defeated in the final minutes of the heat. He will now face Bede Durbidge in round 2, when competition resumes.
AI memorial
A Tahitian ceremony was held today for Andy Irons, a place he will be truly missed.
Another day in Paradise
With swell looking more solid today with perfect conditions, event is looking good to start first day of waiting period tomorrow. Yew
Hello Tahiti
Just arrived in Tahiti / Teahupoo, waves and forecast for Billabong Pro is looking good. Josh Kerr gets his boards ready from our Balcony.
Bali Single Comp
Just had a Bali Single staff and retailer comp, one fin one one life, check the sleds line up, footage coming soon for a laugh!


text:
Rick Owens
Greg Kessler for The New York Times
News about Rick Owens, including commentary and archival articles published in The New York Times.
Chronology of Coverage
Jul. 18, 2013
Rick Owens opens pop-up store in SoHo called DRKSHDW, featuring his secondary line of jeans. MORE
Mar. 4, 2013
Cathy Horyn Paris Fashion Week collections by Celine, Comme des Garcons, Rick Owens and Yohji Yamamoto. MORE
Mar. 15, 2012
Performance artist and rapper Zebra Katz's career is gaining momentum after his song Ima Read played for roughly 11 minutes at the Rick Owens show during Paris Fashion Week. MORE
Mar. 2, 2012
Cathy Horyn reviews latest Paris collections, including offerings from Rick Owens and Balenciaga. MORE
Dec. 8, 2011
Fashion designer Rick Owens introduces his new furniture collection, featuring big pieces made from black plywood, at Maxfield Gallery in Los Angeles. MORE
Sep. 30, 2011
Cathy Horyn reviews Paris Fashion Week collections by designers Nicolas Ghesquiere of Balenciaga, Olivier Rousteing of Balmain, Dries Van Noten, Rick Owens, Marco Zanini of Rochas and Thierry Mugler. MORE
There are no additional abstracts to display.
Rick Owens: Secure in His Own World
The designer lives and works in his building in Paris's Seventh Arrondissement.
September 24, 2014, Wednesday
MORE ON RICK OWENS AND: Owens, Rick , Fashion and Apparel , September Fashion Week (2014) , Paris Fashion Week
A Dual Review of What's New, Starring Rick Owens and Bill Maher
The fashion designer and the stand-up comedian tackle furry shoes, fancy toothpaste and a new film about Nick Cave.
September 8, 2014, Monday
MORE ON RICK OWENS AND: Maher, Bill , Owens, Rick
Cosmic Creations
Designers are going where few have gone before, with everyone from Calvin Klein to Rick Owens getting into a sci-fi state of mind.
August 13, 2014, Wednesday
MORE ON RICK OWENS AND: Owens, Rick , Calvin Klein Inc , Fashion and Apparel , Science Fiction
The Scene | Paris Men's Fashion Week: Rick Owens Spring/Summer 2015
Scenes from the men's fashion week photo diary of Valerio Mezzanotti.
June 26, 2014, Thursday
MORE ON RICK OWENS AND: Owens, Rick , Paris (France) , Men's Fashion Week , Men and Boys , Paris Fashion Week , Fashion and Apparel
From Humble Sneaker to Luxury Icon
Status-symbol men's shoes are having their moment, with some high-end brands selling for more than $1,000.
May 27, 2014, Tuesday
MORE ON RICK OWENS AND: Vans Inc , Adidas AG , Owens, Rick , Tisci, Riccardo , Simons, Raf , West, Kanye , Converse Inc , Paris (France) , Luxury Goods and Services , Fashion and Apparel , Prada SpA , Sneakers , NIKE Inc , Williams, Pharrell , Shoes and Boots , Givenchy , Toronto (Ontario) , Men and Boys
The Next Big Thing in Fashion? Big Things
Huge silhouettes bring to mind giant lizards without predators or monarchs without a clue.
April 24, 2014, Thursday
MORE ON RICK OWENS AND: Watanabe, Junya , Fashion and Apparel , Owens, Rick , Fashion and Apparel , Browne, Thom , Rihanna , Kawakubo, Rei , Marie Antoinette (1755-93) , Pugh, Gareth , Selman, Adam
Bill Cunningham | At Face Value
The fact is, fashion is commerce. But sometimes it can be wearable art.
April 6, 2014, Sunday
MORE ON RICK OWENS AND: Cunningham, Bill , Paris (France) , Owens, Rick , Pugh, Gareth , Comme des Garcons , Watanabe, Junya , Paris Fashion Week , Fashion and Apparel , Art , Booker, Chakaia
Events and Sales Starting the Week of March 13
Just in time for spring, floral sweatshirts and A-line skirts, whimsical accessories and more.
March 13, 2014, Thursday
MORE ON RICK OWENS AND: Rowley, Cynthia , Jewels and Jewelry , Kane, Christopher , Handbags and Purses , Fashion and Apparel , Shopping and Retail , Owens, Rick
In Store | Cozy Baby Separates Designed by a Rick Owens Alum
Asha Mines worked with the designer in Paris for 10 years, walked in his fashion show last month, and now brings her own children's line —made with the same luxe fabrics as her mentor's collection — to New York.
March 10, 2014, Monday
MORE ON RICK OWENS AND: Owens, Rick , Fashion and Apparel
At Rick Owens, Not Your Usual Models
Mr. Owens cast the women close to him, those who work with him in the atelier, the sales showroom, the office.
March 1, 2014, Saturday
MORE ON RICK OWENS AND: Owens, Rick , Models (Professional) , Fashion and Apparel
Runway Photos
Rick Owens Collections
Slide shows of the most recent runway shows.
In the Studio | Rick Owens
Rick Owens chats with Vanessa Friedman about how his creativity used to thrive on chaos before he transformed his five-story building in an upscale Parisian neighborhood into an open ascetic space.
Bill Cunningham | At Face Value
The fact is, fashion is commerce. But it can also be wearable art.
Rick Owens
Men's fall 2013 collections in Paris.
Imitation as Flattery
Who is the most copied designer of the moment, the man whose ideas are irresistable to everyone from Helmut Lang to Banana Republic? Rick's the man.
Rss Feeds On Rick Owens
Subscribe to an RSS feed on this topic. What is RSS?


text:
Comments about 'Ex-President George H.W. Bush in Texas hospital'
- Oldest first
- Newest first
- Most recommended
Ogden, UT
I wish President Bush a quick recovery.
- 5:15 a.m. Nov. 30, 2012
- Like (1)
- Report abuse
Login to comment
DeseretNews.com encourages a civil dialogue among its readers. We welcome your thoughtful comments.
— About comments
What You May Have Missed
Most Popular
Across Site
In U.S. & World
- Security breached: Intruder gets into White...
- 'The Voice' returns Monday with Pharrell,...
- Tense hunt in trooper ambush case hits 8 days
- 11 best—and worst—state tax systems
- Second man arrested trying to enter White...
- After vote to stay in UK, Scots must heal divide
- Secret Service boosts security outside White...
- Actress detained by police refuses to apologize
Most Commented
Across Site
In U.S. & World
- Striking or spanking a child is not a... 19
- School police stock up on free military... 11
- Yellen says US families need to boost... 10
- Security breached: Intruder gets into... 8
- How much America wants to be taxed 8
- New Jersey loses 4th casino as Trump... 5
- Vikings place Adrian Peterson on exempt... 5
- US to assign 3,000 from US military to... 4


text:
Hardly Serious with Jens Voigt
About Hardly Serious with Jens Voigt
Now in his 16th year as a professional, Jens Voigt has earned a reputation as one of the sport's hard men, both among fans and his fellow riders. And the only thing Jens likes as much as riding his bike is talking about it. And that's good for us.
Recent Posts
Commentary on the latest going on in the pro peloton and beyond.
Mixing cycling news, photos, videos, and quick hits from across the web.
Get all the latest on bicycle law, and the social and political issues involved from cycling attorney Bob Mionske.
Selene Yeager writes about training, fitness, nutrition and health.
Sonya Looney brings you real-world advice on eating well, training right, going big, and having more fun on every ride.
Bicycling Newsletter
Get the Bicycling email newsletter FREE. Receive tips & timely articles about the latest in bikes & gear, training, nutrition & more.


text:
Great for every occasion, this is the perfect gift for the gourmet enthusiast who enjoys quality and choice. Learn More
Experience a taste of Sweden with Almnäs Tegel, a hard cow's milk cheese produced by organic farm Almnäs Bruk. With a distinctive child's footprint imprinted on its speckled brown rind, the cheese has a complex savory taste with hints of caramel and grass. Learn More
Great for every occasion, this is the perfect gift for the gourmet enthusiast who enjoys quality and choice. Enter your recipients email address in the shipping address section during checkout for quick and easy delivery! Learn More
The perfect collection for the beer aficionado, Di Bruno Bros. has brewed up this set of select artisan cheeses that will pair exceptionally with your favorite suds. Bottom's up! Learn More
Nothing quite compares to the sweet melody that occurs when cheese and red wine harmonize with one another, although it can be quite difficult to uncover those that are perfect matches. Di Bruno Bros. has done the legwork for you and is proud to bring you our Red Wine Cheese Plate, which features five artisan cheeses that cover every note and style and will pair excellent with red wines. This cheese plate cannot ship via Ground to the western US. Learn More
Having difficulty finding the perfect gift for the big cheese in your life? Look no further. Di Bruno Bros. has packed our signature gift box with classic Italian cheeses and perfect pairings that will delight bigwigs with big appetites. Learn More
Perfect for a gourmet platter or a delicious gift for your favorite entertainer, Di Bruno's famous homemade cheese spreads make a wonderfully creamy experience atop crackers or bread. Spread the fun! Learn More
Products 1 - 7 of 7


text:
Our team of dedicated pharmacy staff is excited to serve your healthcare needs.
Read testimonials from real customers!
Stop in to our pharmacy to learn how we can help you and your family be prepared for the cooler months ahead.
Sleep Aid Plus Pain Relief Caplets 20 ct.
Airborne Dual Action Immune Support Chewable Tablets 32 ct., Effervescent Tablets 10 ct., Tablets 20 ct.
Mucinex, Mucinex DM, Mucinex Allergy 28-40 ct.
Correctol Women's Laxative Tablets 15 ct.


text: VIDEO: Morning Briefing, Sept. 12 Steve Doty • | September 12, 2012 | 12:00 am Topics: Local Local The Morning Briefing is a quick round-up of the day's top stories. Watch online at washingtonexaminer.com every weekday. Sign Up for the Politics Today newsletter! Please enter your email address below to begin receiving the Politics Today newsletter. You must enter a valid email address in the field above! Thank you for signing up for the Politics Today newsletter! You should receive your first newsletter very soon. We're sorry, there was an error processing your newsletter signup. Please click here to visit our Newsletter Signup Center to register for this newsletter. Web URL: http://washingtonexaminer.com/article/2507736 Share this article on Facebook or Twitter Print this article View article comments Leave a comment


text:
While a tour bus driver drives a bus full of seniors down a highway, a little old lady taps him on the shoulder. She offers him a handful of almonds, which he gratefully munches up.
Approximately 15 minutes later, the little old lady taps him on the shoulder again and she hands him another handful of almonds. She repeats the gesture eight times.
At the ninth time, the tour bus driver asks the little old lady why the seniors don't eat the almonds themselves.
The little old lady replies "We are not able to chew them because of our old and brittle teeth."
Puzzled, the tour bus driver asks the little old lady "Then why do you buy them?"
The little old lady smiles at the tour bus driver and says "We just love sucking the chocolate off of them."
Come to Smokin' Joe's Cafe for more laughs Smokin' Joe's Cafe
By Mullookkaaran (Own work) [CC-BY-SA-3.0 (http://creativecommons.org/licenses/by-sa/3.0)], via Wikimedia Commons


text:
Utah's stunning canyons inspired the unique design of this gemstone beaded bracelet. The focal point of this one-of-a-kind bracelet is an angular sterling silver and copper overlay featuring red jasper, tiger eye and picture jasper cabochons. The beaded band is made from red jasper, picture jasper, tiger eye, sterling silver and copper beads. A perfect highlight for your autumn-inspired wardrobe, the bracelet measures 1-1/4" wide. Made in America with gemstones from around the world.
The romance of red rock mesas glowing in the afternoon sun. Inspired by the beautiful rock formations and dramatic stone bridges of Utah's windswept Canyonlands National Park, freeform gemstones of tiger's eye, red jasper and picture jasper float amidst sculptural sterling silver and copper.
Like all fine jewelry, Carolyn Pollack Sterling Silver Jewelry should be handled carefully. Store jewelry in a plastic bag, dry and wrapped in tissue paper, when not being worn or displayed. Clean sterling silver with a silver polishing cloth when necessary, but never subject to chlorine, silver dips, chemical solutions or ultrasonic cleaners, as these substances can cause the genuine gemstones to discolor. Never wear jewelry in a swimming pool.


text:
Visit fine wineries and vineyards on your vacation. Our vineyard tours in Melbourne Australia allow you to participate in the centuries-old craft of wine making. Analyze the appearance, aroma, sensation and finish of each unique wine at our wine tasting. You will learn how a fine wine is crafted from beginning to end on our wine tours in Melbourne Australia. Our winery tours will show you how wine is made, bottled, corked, capped and boxed. See where grapes are grown for wine making and taste the complexity and character behind each unique wine on our wine tasting tours. Browse our wine tasting in Melbourne Australia and plan your vacation today!
|Page:1 of 1
|Sort By:
Wine Tasting Melbourne, Australia - We visit 4 Breweries. These are Buckleys, White Rabbit, Hargreaves Hill and Coldstream and travel at your pace through the Hinterland of Yarra Valley. We stop for Lunch at Hargreaves Hill Brewery. Breweries do NOT OPEN Mon, Tue and Wed.
Wine Tasting Melbourne, Australia - You love good wine good food and you love the undulating countryside which breaths wineries. You would like to enjoy yourself without worrying about anything. Step into a Unique Classic Convertible Chevrolet, feel the spacious comfort and ...
Wine Tasting Abbotsford, Australia - Private Barossa Valley Winery tours with a knowledgeable local wine guide in a 1962 8-seat Daimler Limousine previously used in royal Tours of the sixties. A must for the true wine explorer. Tours to suit, pick-ups, lunch, wine, A/tea all inclusive.
Language Schools Byron Bay, Australia - English language courses for international students and travelers
Hotels & Resorts Leura, Australia - Leura Gardens Resort offers warm country hospitality. Set amidst four and a half acres of landscaped gardens and overlooking the 4th fairway of Leura Golf Course, the Resort offers a relaxing and memorable venue for any occasion.
Hotels & Resorts Parramatta, Australia - Parramatta Waldorf Apartment Hotel provides 41/2 star studio,1 & 2 bedroom hotel apartments accommodation suitable for daily or extended stay. All our hotel apartments are self contain and include full kitchen,laundry & security car parking .
Eco Tours Scarborough Beach, Australia - Discover remote and exciting destinations on our award-winning, professionally escorted, nature-based, soft-adventure, self-drive,small group tours through Outback Australia. Most adventures led by Tour Guide of the Year, Jeremy Perks.
Hotels & Resorts Perth, Australia - Perth central location,overlooking to the Swan River, 5 star 1&2 bedroom hotel apartment accommodation for up to 5 persons . The Winner Of The Australian Award For Superior Accommodation!
Bed & Breakfasts Lyndoch, Australia - 2 fully self contained 2 bedroom cottages set amid an australian bush garden in South Australias' Barossa Valley, Australias premier wine district.
Hotels & Resorts Parramatta, Australia - The Parramatta Waldorf Apartment Hotel is a modern contemporary stylish 4.5 star apartment hotel with new standards of spaciousness and offering accommodation for short or extended stay.


text:
You are currently viewing the beta version of the new AMM site.
Click here
to return to the current site.
Oct 12, 2012 | 11:05 AM
| None
steel market,
hot-rolled coil,
Steel First
SHANGHAI Chinas spot steel market weakened further Friday, with both long and flat products experiencing losses.
Spot prices of Grade III rebar stood at 3,630 to 3,830 yuan ($579 to $611) per tonne in Beijing, down 30 yuan ($5) from Thursday but up 30 yuan from Sept. 28, the last trading day before Chinas national holiday. ....
SHANGHAI Chinas spot steel market weakened further Friday, with both long and flat products experiencing losses.
To access AMM's full content, please log in below. If you do not have an AMM account, we invite you to take a free trial or subscribe below.
Access to amm.com editorial content is granted only to paid subscribers and trialists. If you do not have an active account in your own name, please either subscribe or take a trial and you will have instant access to amm.com content. Sharing your login credentials with individuals who are not subscribers represents a violation of AMM copyright.
Every morning, every minute no matter how often you follow the markets, there's an AMM subscription to fit your needs.
Not sure if you are ready to invest in a subscription right now? Take a free, no-obligation trial. Start your free trial today.
Are you stocking more inventory today than 18 months ago?
We recognize that it takes time to learn to make good, quality steel. And we're not underestimating the need to do that and do it right.
--Mark Bula, Big River Steel


text:
Linen/Cotton Flat Front Short
Item# CFSB0173DS
Color :color
Size & Fit Size :size
Availability :
The Cubavera Cotton/Linen Flat Front Short is the ultimate go anywhere/do anything short, as stylish as it is versatile, and hassle-free as it is cool. These shorts are made of a cotton/linen blend using plainweave fabrication for total comfort, and the flat front cut gives them a contemporary look. Sport them with anything, from one of our Cubavera printed shirts to a graphic tee, or even one of our popular popover shirts.
- 55% Linen/45% Cotton
- Plainweave Fabrication
- Flat Front Short
- Button and Zipper Fly Closure
- 2 Back Welt Pockets with Button Closure
- Machine Washable
- Imported
Rated 5 out of 5 by 1 reviewer.
Rated 5 out of 5 Nice fit and very comfortable I bought these shorts along with several shirts and am very happy with the quality of Cubavera products for the price I paid. May 9, 2013
1-1 of 1


text:
Despite plenty of youtube videos that serve as a warning...
Anhour before their wedding in Crosslake, Minnesota on Saturday, Dan and Jackie Anderson AND their entire wedding party headed out on the dock for the photographer.
Guess what happens next!
Never mind, you can see it coming a mile away.


text:
REVENGE - "Perception" - In an atmosphere of nervous excitement for Emily & Daniel's upcoming engagement party, things quickly start to unravel: Victoria tries to regain the upper hand by using Conrad's own father against him; Jack finds himself wandering deeper into the fray; the rug gets pulled out from under Charlotte, and even more so for Emily, on "Revenge," WEDNESDAY, FEBRUARY 8 (10:00-11:00 p.m., ET), on the ABC Television Network. (ABC/COLLEEN HAYES) JOSH BOWMAN, EMILY VANCAMP, MADELEINE STOWE, WILLIAM DEVANE
Use a Facebook account to add a comment, subject to Facebook's Terms of Service and Privacy Policy. Your Facebook name, photo & other personal information you make public on Facebook will appear with your comment, and may be used on ABC's media platforms. Learn more.


text:
Since I have started my bit**ing about MAG, I have heard some really interesting,horrible,sad,funny accounts from a lot of you ladies.
I think surviving that junk was as bad as the actual sickness of which it saved us from DYING!
We should get "I survived Magnesium Sulfate" t-shirts printed![:D]
Seriously though, I really appreciate the support. Hearing from all of you, really has been healing.
[:X]LOVE[:I] ~Jennifer
Mama to Bella,1/02/03, born 33 and 5/7 weeks at 3 lbs,6oz.Pre-E and PIH,& HELLP.
Babygirl #2,EDD 6/24/04


text:
SCANDAL- "Happy Birthday, Mr. President" - Fitzgerald Grant swears the Oath of Office to become President of The United States.
Use a Facebook account to add a comment, subject to Facebook's Terms of Service and Privacy Policy. Your Facebook name, photo & other personal information you make public on Facebook will appear with your comment, and may be used on ABC's media platforms. Learn more.


text:
Colorectal Cancer Drugs Require Careful Patient Selection
Patients with advanced colorectal cancer who have mutant forms of the gene KRAS in their tumors should not receive chemotherapy plus cetuximab (Erbitux), because they are unlikely to benefit from the treatment and should be spared the side effects and cost, researchers said at the recent American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
Based on a growing body of evidence, including findings presented at the meeting, several experts predicted that it will become standard practice to test all colorectal tumors for mutations in the KRAS gene before starting patients with advanced disease on therapies involving cetuximab and a similar drug, panitumumab (Vectibix).
"I believe it is now warranted to test all patients being considered for these agents," said Dr. Gail Eckhardt of the University of Colorado Denver, who was not involved in the research and discussed the findings at ASCO. "Patients with KRAS mutations should not receive cetuximab or panitumumab in [certain] settings." Read more
Gemcitabine after Pancreatic Cancer Surgery Improves Survival
Patients who received the chemotherapy drug gemcitabine after surgery for pancreatic cancer lived 2 months longer than patients who had surgery alone, according to the final results of a large, randomized clinical trial presented at the ASCO annual meeting last week.
Less than 20 percent of patients with pancreatic cancer are candidates for surgery, because the disease is often detected in the late stages. Gemcitabine has been a standard treatment for patients with advanced (and inoperable) pancreatic cancer for a decade. The new findings support use of the drug in the adjuvant setting. Read more
Colorectal Cancer Drugs Require Careful Patient Selection
Patients with advanced colorectal cancer who have mutant forms of the gene KRAS in their tumors should not receive chemotherapy plus cetuximab (Erbitux), because they are unlikely to benefit from the treatment and should be spared the side effects and cost, researchers said at the recent American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
Based on a growing body of evidence, including findings presented at the meeting, several experts predicted that it will become standard practice to test all colorectal tumors for mutations in the KRAS gene before starting patients with advanced disease on therapies involving cetuximab and a similar drug, panitumumab (Vectibix).
"I believe it is now warranted to test all patients being considered for these agents," said Dr. Gail Eckhardt of the University of Colorado Denver, who was not involved in the research and discussed the findings at ASCO. "Patients with KRAS mutations should not receive cetuximab or panitumumab in [certain] settings."
These drugs are designed to block the activity of the epidermal growth factor receptor (EGFR) protein, which is often overactive in colorectal cancer.
An estimated 30 to 40 percent of colorectal tumors carry KRAS mutations, and commercial tests are available. Screening could proceed based on the breast cancer model, where women undergo testing for genetic characteristics of their tumors prior to treatment with trastuzumab (Herceptin).
"KRAS is the first molecular marker for targeted therapy in combination with standard chemotherapy as a first-line treatment for metastatic colorectal cancer," said Dr. Eric Van Cutsem of Gasthuisberg University Hospital in Leuven, Belgium, at the meeting. "If we know in advance that a patient has a KRAS mutation, then we know we don't have to treat the patient [with these agents]."
He presented new results from the CRYSTAL trial, which last year showed that some patients with metastatic disease benefited from cetuximab plus chemotherapy with respect to progression-free survival. But not all patients benefited and given growing interest in the KRAS gene, the researchers went back and looked at tumor tissue from 587 of the nearly 1,200 patients in the trial.
The results were striking: Only patients with normal KRAS genes benefited. Perhaps most important, findings from other studies, including the OPUS and EVEREST trials, support the findings from the CRYSTAL trial. Retrospective analyses of KRAS gene status and treatment outcomes have now been performed on 1,200 patients with advanced colorectal cancer from separate randomized trials.
"We now have substantial evidence that mutations in KRAS are a negative predictive marker for the use of cetuximab with chemotherapy and for panitumumab as a single agent based on results from a variety of trials," said Dr. Margaret Mooney of NCI's Cancer Therapy Evaluation Program, who was not involved in the research.
Before the meeting, European regulators approved cetuximab plus chemotherapy as a first-line treatment for colorectal cancer in patients with normal KRAS. Panitumumab is approved in Europe for treating advanced colorectal cancer, but also only in patients with the normal KRAS gene.
Prospective studies are now needed to validate the marker. Trials such as CRYSTAL were not designed to answer questions about cetuximab and KRAS, and the researchers do not have tumor tissue from all patients. These patients could provide useful information in developing new therapies.
Dr. Eckhardt stressed the importance of communicating to patients with KRAS mutations that current chemotherapy regimens are effective. "Hopefully," she added, this is "only the beginning of the era of individualized therapy for patients with colon cancer."
—Edward R. Winstead
Gemcitabine after Pancreatic Cancer Surgery Improves Survival
Patients who received the chemotherapy drug gemcitabine after surgery for pancreatic cancer lived 2 months longer than patients who had surgery alone, according to the final results of a large, randomized clinical trial presented at the ASCO annual meeting last week.
Less than 20 percent of patients with pancreatic cancer are candidates for surgery, because the disease is often detected in the late stages. Gemcitabine has been a standard treatment for patients with advanced (and inoperable) pancreatic cancer for a decade. The new findings support use of the drug in the adjuvant setting.
"We have shown that this treatment more than doubles the overall survival 5 years after treatment," said Dr. Helmut Oettle of the Charité School of Medicine in Berlin, Germany, who presented the results.
The study included 368 patients who underwent surgery followed by 6 months of adjuvant gemcitabine treatment or surgery alone. In the gemcitabine group, 21 percent were alive at 5 years compared with 9 percent in the control group. Median survival in the gemcitabine group was 22.8 months compared with 20.2 months in the control group.
Preliminary results from the trial were reported at ASCO in 2005 and showed that post-surgery gemcitabine could delay a recurrence of the disease. These findings led to an increase in the use of the drug in the United States and Europe, according to the researchers.
"We can now say that giving this agent after surgery to patients with early stage disease will improve a patient's survival," commented Dr. Nicholas Petrelli of the Helen F. Graham Cancer Center at the meeting. "We couldn't say that before."
Cetuximab Plus Chemotherapy Extends Survival for Advanced Lung Cancer
Patients with advanced non-small-cell lung cancer (NSCLC) who received cetuximab (Erbitux) plus chemotherapy lived on average 5 weeks longer than patients who received chemotherapy alone, according to results reported at the ASCO annual meeting.
In the phase III FLEX trial, 1,125 patients with all types of NSCLC were randomly assigned to receive standard platinum-based chemotherapy alone or chemotherapy plus cetuximab. Nearly all of the patients had stage IV disease. Overall survival was higher for those who received cetuximab plus chemotherapy (11.3 months) compared with those who received chemotherapy alone (10.1 months).
The benefit of the combination therapy was seen in patients with all histological subtypes of NSCLC, including adenocarcinoma and squamous cell carcinoma, the two most common subtypes. The main side effect was an acne-like skin rash that could be managed.
"Patients with advanced NSCLC have limited treatment options and life expectancy is short, so the survival increase shown in this study is an important step for these patients," noted Dr. Robert Pirker, an associate professor of medicine at the Medical University of Vienna in Austria and the study's lead author.
The only other final-stage randomized trial to show a survival benefit in lung cancer was a 2005 study of bevacizumab (Avastin) plus chemotherapy. Unlike the current study, that trial did not include patients with squamous cell carcinoma.
Dr. Thomas Lynch of Massachusetts General Hospital, who commented on the findings at ASCO, said the study was well done and produced "a clinically meaningful benefit for a large population."
Zoledronic Acid Improves Early Breast Cancer Treatment
The addition of zoledronic acid (Zometa) to adjuvant endocrine therapy in premenopausal women with early stage breast cancer significantly improves clinical outcomes beyond those achieved with endocrine therapy alone, researchers reported at the ASCO annual meeting. The results are from a phase III randomized trial of 1,800 women conducted by the Austrian Breast and Colorectal Cancer Study Group.
Zoledronic acid, part of a class of drugs known as bisphosphonates, is already used to treat bone metastases, and this trial was conducted based on data from preclinical and early phase trials indicating that the drug can also shrink tumors and block metastatic activity. The results bear this out, said principal investigator Dr. Michael Gnant from the Medical University of Vienna.
Overall, the trial showed no difference in disease-free survival between women treated with tamoxifen or anastrozole. But the addition of zoledronic acid to either therapy decreased the risk of a disease-free survival event by 36 percent compared with hormone therapy alone, Dr. Gnant said. At a median follow-up of 60 months, overall disease-free survival was 92.4% and overall survival was 97.7%.
Women in the trial - all of whom were premenopausal with stage I or II breast cancer that was responsive to endocrine therapy - were treated with surgery and, if needed, radiation therapy. They also received the drug goserelin to temporarily suppress the function of the ovaries. Each was randomly assigned to one of four adjuvant therapy arms: tamoxifen alone, the aromatase inhibitor anastrozole alone, or either drug plus zoledronic acid. Treatment lasted 3 years.
The drug was also well tolerated, with no indication of increased risk of liver problems or damage to the jaw bone - two side effects which have been associated with higher doses of bisphosphonate drugs.
Acupuncture Tested in Cancer Patients after Neck Surgery
For patients with head and neck cancers who undergo a surgical procedure known as neck dissection, acupuncture may help reduce pain and improve functioning afterward, according to preliminary findings from a randomized trial presented as a poster at ASCO.
"Acupuncture appears to be a promising treatment for these patients, and more research is warranted," said Dr. David Pfister of Memorial Sloan-Kettering Cancer Center, who discussed the results at ASCO. Conventional treatments have limited success in helping patients following neck dissections, he noted, and "there is plenty of room for improvement."
The study included 34 patients who received acupuncture and 36 who received standard care with pain medication and physical therapy. In the experimental group, four sessions of acupuncture were administered over the course of a month. A standard set of acupuncture points was used for each patient, and more specialized points were selected depending on the pain for each individual.
Thirty-nine percent of the patients who received acupuncture had significant improvements in pain and function, compared with only 7 percent who experienced improvement in the standard care group, according to assessments using a measure called the Constant-Murley scale. Some patients in the acupuncture group had significant relief of dry mouth, while no relief was observed in the patients receiving standard care.
Future studies may include a group that receives "sham" acupuncture to control for the placebo effect.
Protein Biomarkers Point to Early Stage Pancreatic Cancer
Researchers have discovered proteins in blood that reliably indicate early stage pancreatic cancer, according to a report June 10 in PLoS Medicine. Although more research is needed before an actual diagnostic test could be developed, the study's lead author, Dr. Samir Hanash from the Fred Hutchinson Cancer Research Center, said the study represents a "breakthrough in the application of advanced proteomic technologies and mouse models to cancer-biomarker discovery."
The mouse model used in the study was genetically engineered to mimic the course of pancreatic cancer in humans, from development of precancerous lesions through advanced disease. Using proteomic technologies, the researchers identified a panel of five proteins - LCN2, REG1A, REG3, TIMP1, and IGFBP4 - consistently found in mice with precancerous growths called pancreatic intraepithelial neoplasia, but not in mice with full-blown cancer or healthy control mice.
To validate the five-protein panel, they tested it against blood samples from 13 people in an unrelated cancer prevention study who developed pancreatic cancer within a year of donating the sample. The researchers were "blinded" to which samples came from cancer patients and controls. The five-protein panel consistently identified samples from the patients who developed cancer, and when it was combined with another protein marker, CA19.9, which is elevated in up to 80 percent of newly diagnosed pancreatic cancer patients, the test was even more accurate.
The next steps include studies to validate the biomarker panel's performance in distinguishing between pancreatitis (inflammation of the pancreas) and pancreatic cancer - under the auspices of NCI's Early Detection Research Network (which also partly funded this current study, along with NCI's Mouse Models of Human Cancers Consortium) - and continued studies to assess its value in early detection among those at high risk of pancreatic cancer.
Initial Costs of Cancer Treatment on the Rise
In the first study to examine trends in the costs of specific components of initial cancer care in the United States, investigators found that Medicare payments for initial treatment rose significantly for breast, colorectal, and lung cancer patients but dropped slightly for prostate cancer patients between 1991 and 2002. These results, published online June 10 in the Journal of the National Cancer Institute, highlight the financial challenges to Medicare posed by the rising number of cancer patients in the United States as the population ages, the study authors said.
The investigators used the linked Surveillance, Epidemiology, and End Results-Medicare data from 306,709 newly diagnosed breast, colorectal, lung, and prostate cancer patients age 65 or older. Specific services evaluated included cancer-related surgery, chemotherapy, radiation therapy, and hospitalizations during the initial treatment period (defined as from 2 months prior to 12 months following diagnosis). The investigators assessed the proportion of patients who were hospitalized, received cancer-related surgery, chemotherapy, and radiation therapy, as well as the average cost per patient for those services.
After adjusting for inflation, the investigators found that between 1991 and 2002 the average cost per patient rose $7,139, $5,345, and $4,189 for lung, colorectal, and breast cancer, respectively. Prostate cancer costs decreased by $196, due to a decline in the use of radical prostatectomy. The most significant increases were due to the percentage of breast, lung, and colorectal cancer patients receiving chemotherapy and the average cost per patient for chemotherapy. Over this time period the proportion of breast and prostate cancer patients receiving radiation therapy increased, as did the cost of radiation therapy. However, hospitalizations during the initial treatment period accounted for the greatest portion of total Medicare payments.
The study ended before the introduction of new, more expensive chemotherapies and targeted therapies such as erlotinib and bevacizumab, noted the authors. "Evaluation of the impact of these new agents on total Medicare expenditures for initial cancer care will be a priority for future research," said the lead author, Dr. Joan Warren from NCI's Division of Cancer Control and Population Sciences.
Dr. Niederhuber's Remarks at the ASCO Opening Session
The following is an abridged version of the prepared remarks delivered by NCI Director Dr. John Niederhuber on May 31 during the opening session of the 2008 ASCO Annual Meeting in Chicago, IL. This text represents the basis of his remarks and may have been modified slightly during delivery.
Good morning and thank you for asking me to appear before you today. … We are extremely fortunate to have such outstanding leaders of [ASCO] - individuals who so clearly understand the times we live in and the challenges and opportunities that lie before us - as we lead a transformation of science and medicine in the post-human-genome era. Among our many challenges, there is none, I believe, greater than the necessity that we more rapidly translate our discoveries, our new interventions, to patients.
As oncologists, as cancer physicians, we become intimate with the fears of our patients. Sitting at the bedside, gazing into the frightened, tearful eyes of far too many men, women, and children just learning they have cancer, we know that statistics are never simply numbers. They are very real individuals, each in his or her own way grasping to cope with news that, as a young physician being treated for Hodgkin disease recently reminded me, "is a life-changing event."
Recently, cancer has deeply touched us. Last year, at this podium, we honored a lifetime of dedicated service and leadership by our great friend and revered colleague Marty Abeloff. This year, we are all diminished by his absence. His loss, although months past, is still fresh, still palpable, and still painful to his colleagues and friends.
We also remember - I, especially - Judah Folkman, a legendary surgeon, educator, and researcher, whose skill, vision, and compassion we dearly miss and shall never forget.
Cancer intrudes into our national consciousness, as well. Just a few weeks ago, the Honorable Edward Kennedy chaired a special hearing of the Senate Health, Education, Labor, and Pensions Committee to consider ways our country could invest in and reinvigorate its collective efforts against cancer. Today, Senator Kennedy is courageously negotiating the treacherous path of the very disease he has worked so hard, for so many years, to fight. It is impossible to escape the irony that one of the architects of the landmark National Cancer Act of 1971 now turns his battle inward.
I daresay none of us has escaped cancer's scars, whether we wear those marks personally or symbolically, on behalf of a loved one.
As a nation, I believe we must confront the fact that a rapidly aging population and its cancer burden will weigh heavily, not only on health care, but on the workforce and our economy. As cancer researchers and cancer physicians, we face an inescapable question: Can we sustain our momentum and continue to lessen the all too devastating impact of cancer?
I believe that we are all here in Chicago this week, thousands strong, to resoundingly answer: "Yes."
We are here to listen and learn and share and discuss - and even debate - the promise of science and the assurance that we will not rest until that promise is delivered to all of our cancer patients, whether they seek treatment in a world-renowned university cancer center or in a rural community hospital. And we must resolve to consign to history the inequalities of cancer treatment that arise from age, frailty, race, ethnicity, poverty, and language.
As director of the National Cancer Institute - your National Cancer Institute - I stand here this morning to recommit NCI to make every effort toward the healthy tomorrows we all envision. I extend this promise fully aware of the challenges [presented by 4 straight years of funding that have been consistently below the rate of medical inflation].
I also know that our cancer patients don't want to hear explanations about flat budgets. They want prevention options. They want effective, novel therapies. NCI has an obligation, to our patients and to our country, to set the agenda for and to facilitate cancer research in the decades ahead. I believe, as well, that NCI is uniquely poised to bring together industry, academia, and government in the search for solutions none could provide by itself.
We come together during a time of unparalleled discovery, of rapidly mounting information about the alterations of the code of life that become aberrant and lead to cancer. Consider, if you will, The Cancer Genome Atlas, often called TCGA for short, to denote the four DNA bases. Co-sponsored by NCI and our sister NIH institute, the National Human Genome Research Institute, this 3-year pilot project is an effort to test the feasibility of large-scale characterization and sequencing of patients' tumors. We have sequencing centers up and running, along with tissue characterization centers making sure samples archived for sequencing (up to 500 samples of both tumor and matched normal tissue) are of sufficient quality.
The first cancers being studied in this pilot program are lung, ovarian, and glioblastoma multiforme. In part, because high-quality tumor tissue has been available, glioblastoma has led the way in this effort. To date, more than 234 tumors have undergone comprehensive characterization and 1,300 genes have been sequenced, and some fascinating associations have been revealed - specifically, two genes that are highly associated with glioblastoma: NF1 and Erbb2. Neither of these genes was previously known to have an association with this disease. In addition, previously unknown changes in the EGF receptor and the p53 tumor suppressor gene are now known to be part of glioblastoma's course. Based on this new, very preliminary analysis, at least four general subtypes of glioblastoma are emerging.
Tumor sequencing of this sort, along with the rapidly advancing field of whole-genome scanning, are, without a doubt, at the forefront of cancer science. Yet, for now, this is just information: a collection of T's, C's, G's, and A's. Our challenge is to convert this powerful information into knowledge of how gene expression is transcriptionally regulated; how that expression is translated into proteins affecting signal pathways; and how these changes eventually alter tissue function and disease phenotype. These determinations will not be easy.
Ultimately, the power of the genome will be to push forward the development of new strategies in prevention, new opportunities for early detection, essential biomarkers of disease, and, of course, novel drugs and new treatment approaches. We must be focused on enabling translation.
This need was made clear in a report in 2007 of NCI's Translational Research Working Group, which spent 2 years conducting a detailed analysis of how to realize the power of a bench-to-bedside approach. The report called on NCI to tailor both new and existing programs to facilitate early translational research progress. NCI is working hard to answer the report's call in five key ways.
The first area is clinical research. We are fortunate to have, on the NIH campus in Bethesda, the world's largest hospital principally devoted to clinical studies. It is the home to a dedicated cadre of NCI intramural science programs and scientists. But we have also come to believe that, in order to facilitate the best translational efforts, this outstanding facility should become a resource for the extramural community. For the first time, we have a trial open with an extramural co-principal investigator, and there are several more such trials pending.
Additionally, we are reaching out to both the new Walter Reed National Military Medical Center, which is due to begin construction across the street from NIH this summer, and Suburban Hospital, which is across the street on the other side of campus. These two facilities have the potential to give us an opportunity to work on prevention and to see more early stage patients.
Our second goal is drug development. NCI often works with orphan opportunities: small molecules and biologics that are not being developed by industry because they lack a significant market share or they are too risky to pursue. We must enable that work. We see drug development as a platform that encompasses a new chemical biology consortium and extends NCI's Developmental Therapeutics Program. We have a duty, I believe, to develop new agents and to carry them forward to first-in-human studies.
Drug development will make our third goal essential: Reaching out to work with both the Food and Drug Administration and the Centers for Medicare and Medicaid Services, connecting regulators and those responsible for reimbursement. Just one example is our Interagency Oncology Drug Task Force that, among other functions, sponsors NCI-FDA fellowships to train young scientists in research and in research-related review, policies, and regulations.
Public-private partnerships will also be increasingly necessary. As we move to a more personalized era of oncology, it is clear that we will require multiple agents to target multiple pathways in the same patient. Facilitating that future will challenge how we think of competition, intellectual property, and even the language of contracts. I believe NCI must step into those areas and become the facilitator between the public, private, and academic sectors. I believe it is a fair question to ask: If not NCI, then who will lead this absolutely vital effort?
Fifth and finally, if NCI is to appropriately facilitate translation, we must make every attempt to provide stable funding for some of the most important programs at the heart of translational research. Specifically, I am referring to clinical trials, the Specialized Programs of Research Excellence (SPOREs), the Community Clinical Oncology Program (CCOPs), and the Cooperative Groups.
Although it is entirely possible that NCI's below-inflation funding may continue for several more years, we will do - and must do - all we can to keep these crucial programs vigorous.
Overarching all that we do, NCI has a duty to make every effort to reduce the disparities that affect cancer prevention and treatment. I am convinced that access to our latest science will be the greatest determinant of cancer mortality in the years to come.
To address this we are now beginning the second year of our NCI Community Cancer Centers pilot program, a research effort to study how we can best bring state-of-the-art, multi-specialty care, and earliest-phase clinical research - phase I and phase II studies - to patients in the communities where they live. It gives me great pride to hear the 16 community hospital [pilot] sites report on their enthusiastic efforts, and how much they have been able to leverage the modest funding provided by NCI. It is also extremely gratifying to know that these pilot sites, seven of which have links to the CCOP program, are participating in ASCO's Quality Oncology Practice Initiative.
All of NCI's efforts - and certainly all of your efforts as oncologists - are about individuals with cancer. We have made many, many advances, and today we are witnessing perhaps the most exciting era in science's history.
I would like to conclude this morning with the story of a patient. It is a story not about a common occurrence or even one that may be replicated. It is a story about the power and the importance of your National Cancer Institute. It is a story of NCI's work in drug development and of facilitating early translational research.
When our patient arrived at the NIH Clinical Center, she couldn't even make a fist. Her hands, wrists, elbows, and knees could scarcely bend. Her skin was cracking, and she suffered the pain of many open skin lesions. Her face was swollen and disfigured. A once-vibrant woman in her late twenties, she was now severely anemic, wheelchair bound, and wrapped in blankets to preserve the body heat her skin could no longer retain. Over 2 years, as she suffered the disabling and constantly progressive manifestations of cutaneous T-cell lymphoma, the nights spent in the hospital had come to greatly outnumber those spent at home.
She was in hospice care and lacked the strength to be with her two small children. She came to the Clinical Center virtually out of treatment options, and once there, an initial short list of experimental treatments all failed.
Having apparently run out of hope, our patient's story came to the attention of Dr. Martin Gutierrez, a staff clinician with NCI's Medical Oncology Branch. Dr. Gutierrez, who has spent his career working with T-cell lymphoma patients, suggested trying a new drug being developed through NCI's well-known RAID Program. The Rapid Access to Intervention Development Program, as you are well aware, exists to speed the translation of novel anticancer therapies from our laboratories into first-in-human studies.
The drug utilized by Dr. Gutierrez, fenretinide, was one that was developed but never marketed by a pharmaceutical company as a chemopreventive agent. It was brought to the RAID program by an extramural investigator from Los Angeles, who wanted to reformulate it as a potential chemotherapeutic drug, based on observations he had made in laboratory models.
In this case, the drug paid off, and paid off dramatically. Within the first few doses, Dr. Gutierrez began to see remarkable improvement. Within 7 months, the patient's symptoms were completely gone. Today, almost 2 years after her arrival at the Clinical Center, the patient's tests show no evidence of disease.
To me this story - not a report of a large clinical trial, but involving just one patient - illustrates many aspects of the role of NCI. It was not the most common cancer problem and not the most common potential therapeutic compound. Instead, it is a great example of the partnerships between the extramural community and NCI in the development of novel agents. It is, I believe, an example of the increasing need for the development of new therapies that are not attracting the prime interest of the private sector. It is about knowing the science and using that knowledge to drive drug discovery; about using genetics to drive high-throughput screening; about the power of a large workforce of chemists to address formulation; and about scientific opportunity, without the consideration of shareholder profit.
We are all looking to the day when stories like this are commonplace, when we make cancer a more chronic, manageable condition.
We have many miles and, yes, a few mountains ahead of us on [our] path. My commitment to you is that your National Cancer Institute will walk beside you, helping you negotiate every step.
May our days here in Chicago renew our spirits, renew our commitment, and recharge us for the walk ahead. Thank you for all you do and for your support, and thank you for being here this morning.
Ovarian Cancer Study Could Speed Early Detection
Can a simple blood test detect early signs of ovarian cancer? This question has been asked repeatedly over the last decade, and an answer may finally come this summer.
In a closely watched study, five research groups are validating their most promising ovarian cancer markers using high-quality blood samples from the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial, including some prediagnostic samples from women who developed ovarian cancer during the trial.
The validation study, coordinated by NCI's Early Detection Research Network (EDRN), could show whether panels of markers can detect ovarian cancer in blood collected 6 months or more before cancer was discovered. If markers do predict ovarian cancer, the question then becomes: How long before a clinical diagnosis are the markers informative?
Earlier is always better, and for this disease in particular. Ovarian cancer has been called a "silent killer" because the vast majority of cases go undetected until the later stages, when women have few treatment options. The hope now is that a blood test for early detection is within reach.
"Everybody has a real sense of urgency now," said Dr. Daniel Cramer of Brigham and Women's Hospital, who leads one group. "We've been saying for years that we'll get a marker for ovarian cancer, but it hasn't happened yet. This is the first good test to see if we can come up with a panel of markers for ovarian cancer from PLCO samples."
The PLCO is one of several large, randomized studies that have been making limited samples available for biomarker research based on proposals from investigators. These studies have rare prediagnostic samples that were collected before anyone knew that a person had a particular cancer. Such samples are considered "more pure" and may more accurately reflect the biology of ovarian cancer than other specimens.
The vast majority of prediagnostic blood samples for ovarian cancer are collected from women just prior to surgery for a suspected ovarian tumor. But impending surgery and anesthesia, for example, might alter at least some potential markers in women with the cancer but perhaps not in a comparison group.
Similarly, in the validation study, great care was taken to eliminate factors that, in the end, could mislead investigators.
"If the biomarkers do not detect ovarian cancer in these samples, it will be because of the biology of ovarian cancer and not because of how the study was designed or implemented," said Dr. Christine D. Berg of NCI's Division of Cancer Prevention and the leader of PLCO.
The validation study is being managed by Dr. Christos Patriotis of NCI's Cancer Biomarkers Research Group with Dr. Sudhir Srivastava, who heads the EDRN program.
The study could yield a variety of markers, including some that improve the sensitivity of the protein CA-125 test. This marker is routinely evaluated when diagnosing ovarian cancer, but it cannot be used alone because only some women with ovarian cancer develop elevated levels, and levels can be elevated for reasons other than cancer.
"Many potential biomarkers have been proposed to be added to CA-125 for the early detection of ovarian cancer, and the PLCO samples will help us select the most promising of those markers," said Dr. Robert Bast, Jr., of the University of Texas M.D. Anderson Cancer Center, who discovered CA-125 and is an investigator in the study.
Beyond early detection and diagnosis, markers are needed to assess risk and guide difficult clinical decisions. For instance, some women with genetic risk factors for breast and ovarian cancers have their ovaries and fallopian tubes removed as preventive measures after childbearing years.
The validation study could yield markers that identify women without the risk genes who nonetheless have a high risk of the disease within 5 to 10 years. Other markers could identify women who have a family history of ovarian cancer but are at such low risk that they could safely avoid preventive surgeries, at least in the short term.
Before any of these markers can be used in the clinic, they would need to be tested prospectively, and the challenges of early detection are substantial.
"It may be helpful to think about what we're trying to do," said Dr. Nicole Urban of Fred Hutchinson Cancer Research Center, another lead investigator. "With a screening program, a woman comes in and you get a blood sample and try to predict if she's going to be diagnosed with cancer. You're trying to find cancer that would kill the woman, but you're trying to find it early enough that you can cure it. And this is tough."
Dr. Urban is nonetheless optimistic that screening for ovarian cancer using markers will ultimately succeed. She predicts that serial blood samples from randomized trials may be required to discover the markers and track their changes over time.
"There is no single marker that will be sensitive enough to distinguish all the ovarian cancer patients from healthy women," said Dr. Gil Mor of Yale University, who leads the fourth group. His team has developed panels with two types of markers - proteins produced by ovarian tumors and proteins produced by the body in response to very early changes associated with ovarian cancer.
All of the groups have taken essentially similar strategies, noted Dr. Anna Lokshin at the University of Pittsburgh Cancer Institute, the principal investigator for the fifth study group. "We are all now waiting for the results." The data are being analyzed, and answers could come within months.
"A lot of people around the country are holding their breath to see the results," said Dr. David Ransohoff, a cancer epidemiologist at the University of North Carolina at Chapel Hill, who consulted on the project.
"These are some of the best groups in the country; they are investigating an important question; and the specimens are among the best available to answer it," he continued. "If the results are positive in these samples, it will be enormously good news for the field."
—Edward R. Winstead
FDA Conducting Safety Review of TNF Blockers, Adds Warning to Becaplermin
The Food and Drug Administration (FDA) is investigating the possible association between drugs known as tumor necrosis factor (TNF) blockers and the development of several cancers, primarily lymphomas. The drugs - sold in the United States as Remicade, Enbrel, Humira, and Cimzia - are used to treat children and young adults for juvenile idiopathic arthritis and Crohn disease, as well as other diseases, FDA explained in an "early communication" about the investigation.
The review follows 30 reports of cancer in children and young adults (age 18 or under) submitted via the agency's Adverse Event Reporting System since 1998, when the first TNF blocker was approved. Of the cancers reported, FDA said, approximately half were lymphomas, including Hodgkin and non-Hodgkin lymphoma.
"While cancers are known to occur in children and young adults, the reports of these events in children and young adults receiving TNF blockers are of concern and deserve further investigation," FDA said. "Long-term studies are necessary to provide definitive answers about whether TNF blockers increase the occurrence of cancers in children because cancers may take a long time to develop and may not be detected in short-term studies."
Last week, FDA also announced that it was adding a boxed warning to the prescribing information of becaplermin (Regranex), a topical cream indicated for the treatment of leg and foot ulcers that are not healing in diabetic patients, about an increased risk of cancer mortality associated with use of three or more tubes of the product.
The warning, FDA explained, is based on the results of two studies that have shown an increased cancer mortality risk among those who have used three or more tubes of becaplermin. In one retrospective study, such use of becaplermin, a recombinant human platelet-derived growth factor, was associated with a five-fold increased risk of cancer mortality.
The studies did not identify any specific cancers for which the product might increase mortality risk.
Wlodawer Awarded Heyrovsky Medal
Francis Collins Leaves NHGRI
NIH Director Dr. Elias Zerhouni referred to Dr. Collins as a "trailblazer in the scientific community." Dr. John Niederhuber, director of NCI, also praised Collins' leadership noting NHGRI's partnership with NCI during the pilot phase of their joint venture, The Cancer Genome Atlas. This landmark project to understand the molecular basis of cancer through genome characterization "is an example of the kind of groundbreaking research two institutes can create, when their focus is on nothing less than the best science for the benefit of patients," Dr. Niederhuber commented. "What Dr. Collins has contributed to these pioneering efforts will one day transform cancer medicine."
Free Telephone Workshop for Cancer Survivors
This is the third of a three-part telephone education workshop series called "The Sixth Annual Cancer Survivorship Series: Living With, Through, and Beyond Cancer."
Part I, "The Importance of Communicating with Your Doctor about Follow-Up Care," took place on April 22, and Part II, "Rediscovering Intimacy in Your Relationships Following Treatment," took place on May 13. Both workshops are archived on the CancerCare Web site.
No phone charges apply. However, pre-registration is required. To access the archive or to register, go to http://www.CancerCare.org/TEW.
Defining Therapy for Recurrent Platinum-sensitive Ovarian Cancer
Name of the Trial
Principal Investigators
Why This Trial Is Important
Typically, ovarian cancer is treated with surgery to remove the cancer, followed by combination chemotherapy with a platinum-containing drug (carboplatin or cisplatin) and a taxane, such as paclitaxel. Ovarian cancer that responds to chemotherapy with a platinum-containing drug is called platinum sensitive. Even if it recurs after treatment, platinum-sensitive ovarian cancer may respond again to treatment with a platinum-taxane combination.
While this common therapy does help some women live longer, doctors are eager to find better ways to treat recurrent ovarian cancer. One method under investigation is the addition of the biological agent bevacizumab to combination chemotherapy. Bevacizumab works by blocking the development of new blood vessels to tumors. Another approach, called secondary cytoreductive surgery, is performing another operation to remove the recurrent tumors.
In this phase III clinical trial, women with platinum-sensitive, recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer will be assessed first to determine whether or not they are candidates for secondary cytoreductive surgery. Surgical candidacy will be determined by whether or not there is a high likelihood of complete tumor removal, based on clinical evaluation and imaging. Women found to be candidates for this surgery will be randomly assigned to undergo it or not. These women will then be randomly assigned to receive combination chemotherapy with carboplatin plus paclitaxel or the same chemotherapy plus bevacizumab, followed by maintenance bevacizumab therapy after the chemotherapy is completed.
Women who are determined to not be candidates for secondary cytoreductive surgery at the start of the trial will immediately be randomly assigned to receive carboplatin plus paclitaxel chemotherapy or the same chemotherapy plus bevacizumab, which will also be followed by maintenance bevacizumab.
"At this point, the optimal therapy for women with recurrent, platinum-sensitive ovarian cancer is not well defined," said Dr. Coleman. "We have seen positive results from both of these experimental therapies in early stage clinical trials, and with this trial, we are hoping to establish their benefits for women with these cancers."
For More Information
An archive of "Featured Clinical Trial" columns is available at http://www.cancer.gov/clinicaltrials/ft-all-featured-trials.
Cancer.gov en Español Celebrates First Year, Looks Forward to Growth
An announcement last month by the U.S. Census Bureau noted that Hispanics and Latinos are not only the largest minority group in the country, but they are also the fastest growing. In anticipation of their health information needs, NCI launched a Spanish-language Web site, Cancer.gov en español, in April 2007.
"Although Latinos in this country represent a diverse population with respect to cultures, Cancer.gov en español is an important step in the right direction to meet their information needs," says Nelvis Castro, associate director of multicultural and international communications in NCI's Office of Communications and Education (OCE).
The site has had strong reviews, including six NIH Plain Language Awards, an NIH Director's Award, and more than 140 articles publicizing the site across various national Spanish-language markets, including CNN en Español. After it launched, the number of visitors to NCI's Spanish-language Web pages jumped by 10 percent.
"It's not always easy to find relevant and appropriate cancer information in Spanish, but Cancer.gov en español offers this in one easy-to-access Web site," says Dr. Yvette Colón, director of education and internet services at the American Pain Foundation. "We provide several links to it from our Web site, and our Pain Information staff members regularly include it as a resource for callers."
By 2007, many NCI materials were already available in Spanish, notes José Acosta, a technical writer and editor in OCE. "What we needed to develop was a new Web site structure," he says, "one that would be proper for the cultural needs of Latinos."
Among the approximately 46 million Latinos living in the U.S., about half can speak English comfortably. Research shows, however, that Spanish messages have a stronger emotional impact on Latinos than those written or spoken in English. And even among second-generation immigrants, culture influences their preference for images and content that reflect their heritage.
NCI addressed these trends by designing a Web site for Latinos living in the U.S. who are confronting cancer personally, as family members of a cancer patient, or as health professionals seeking cancer research information in Spanish to provide to their patients.
"We're trying to address the myths and beliefs that exist within the Latino community around cancer right from the home page," says Anne Middleswarth, a Web content manager in OCE. Four homepage banners highlight cancer prevention, treatment, detection, and survivorship, and lead to content that corrects misunderstandings about the topics.
"It's become a tool for navigating the health care system," explains Silvia Inéz Salazar, a public health advisor in OCE. She points to the Spanish-language dictionary on the site, which contains more than 5,000 entries and allows people to toggle back and forth between the Spanish and English versions of cancer terms. She notes that both patients and health care providers have used this translation function to improve their communications.
Members of offices across NCI have helped with content development and promotion of Cancer.gov en español. For example, information specialists at the NCI Cancer Information Service call center in Miami, FL, which answers Spanish-language inquiries from the public, helped test the site before it went live, providing valuable feedback on navigation and the search engine.
The site will continue its expansion in 2008, with targeted development of new pages that reflect the areas of greatest interest and need among Spanish-speaking audiences.
—Brittany Moya del Pino


text:
Today: Clear start to the day after the fast moving storms last night. Partly cloudy skies by this afternoon with a slight chance of isolated showers. Mostly dry except for mountains across our northern interior. High: 80Tonight: Partly cloudy skies. Low: 56Tomorrow: Partly cloudy to mostly sunny skies but again the chance of mountain showers. High: 83 (Green)
KHQ.COM - Avista is reporting 12,000+ customers without power as of 9:20 Sunday night. Crews are working on restoring power, and will be busy throughout the night.
For the very latest numbers on power outages in the area, CLICK HERE


text: The series consists of ~822 documentaries produced by the United States Army Signal Corps Army Pictorial Service from 1951 to 1971 to educate both soldiers in uniform and the American public about military concerns as well as things like historical battles, world geography, famous soldiers, the latest weapons, space exploration, strategic objectives, peaceful initiatives, and the life of a soldier. Being a product of the Federal Government it belongs to the the American people, and is thus freely available to all to copy and distribute. Most can now be viewed on archive.org[more inside]


text:
Wondering if you'll need rain gear for you morning bus trip or afternoon ride home? Ask Alan!
Get a bird's eye view from the Sutton Avian Research Center Live Bald Eagle nest camera.
Learn more about weather events that affect Oklahomans
See where weather is happening using our live interactive radars.
See it! Shoot it! Send it! Share your weather pics and videos with NewsOn6.com!
Get alerts sent to your cell phone or email when watches and warnings are issued for severe weather.
See where weather is happening using our live interactive radars.
When there is breaking news across the state Osage SkyNews 6 can be first on the scene.
Watch tornadoes tear across Oklahoma and learn how to stay safe!


text:
Question: Where is the ""A"" list crowd going these days? Answer: Hard to say, but the Lion is sure to find out!
Travel is all about status for these pampered pets, so being with the incrowd counts for a lot, as do creature comforts once there. Wimbledon in June is a must, at which time the Lion will stay at the Ritz and dance till dawn at London's snazziest clubs. Paris is perfect in the springtime, while Milan is a must during the fall fashion shows.
Many Leos enjoy gambling, so Las Vegas is high on their list -- a little craps at Caesars Palace sounds about right. Lovers of romance as well, a Lion will purr like a kitten if swept away for a romantic weekend along the Mendocino coast (the Heritage House being the definitive inn). Leos aren't likely to roam much around India or Africa, though, as the thought of those less fortunate than themselves is a bit hard for them to handle.
Are you on the right path? Find out with a free sample Life Path Reading from Astrology.com.
*DISCLAIMER*: The information contained in or provided through this site section is intended for general consumer understanding and education only and is not intended to be and is not a substitute for professional advice. Use of this site section and any information contained on or provided through this site section is at your own risk and any information contained on or provided through this site section is provided on an "as is" basis without any representations or warranties.


text:
Showing 1 - 2 of 2 Products
Model: VX137-BLK |
Catalog #: 55066080
Capture life's memorable moments on the Vivitar 12.1 Megapixel VX137 Digital Camera. This camera is ...
See the Full Product Details
Model: VX022-BLU |
Catalog #: 55066078
Great quality, user-friendly controls, and an excellent value define the VX022 Digital Camera. A res...
See the Full Product Details
Online prices and product selection may vary from our retail stores. All prices and offers are subject to change. Copyright RadioShack Corporation 2014. All rights reserved.


text: If you missed the Halloween episode of Ellen yesterday there is one part you have to see. Ellen sent her writer Amy and producer Jeff to The Queen Mary's Dark Harbor Circus Maze. It is pretty safe to say they didn't enjoy it. The only thing better than going to a haunted house is watching others do it.


text:
About this artwork: This foto was taken in Thailand few months ago. I have manipulated it a bit in Photoshop.
Digital Arts
19,274 views | 1 collections | Added Jan 1, 2006
Contact Artist
See all Artworks by Anax (11)
Order a custom work by Anax! Are you interested by a custom artwork from Anax ? To enquire about customizing an existing artwork, or create a completely new project based on your requirements, please contact the artist and provide all details about your project. Artist will be back to you within 48h.
Contact Artist
Follow Anax!


text:
Moderators: Jenise, David M. Bueker, Robin Garr
David M. Bueker wrote:That '96 Krug was one heck of a wine. I've had it three times now, and it's always absolutely fantastic.
Cedric Bouchard wines have always been good, but never really struck me as great.
Users browsing this forum: Google Adsense [Bot], Majestic-12 [Bot], TomHill, Yahoo [Bot] and 9 guests